169 related articles for article (PubMed ID: 32623551)
41. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.
Quiney C; Billard C; Faussat AM; Salanoubat C; Kolb JP
Leuk Lymphoma; 2007 Aug; 48(8):1587-99. PubMed ID: 17701591
[TBL] [Abstract][Full Text] [Related]
42. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
43. Resveratrol-mediated reversal of tumor multi-drug resistance.
Hu Y; Li C; Li H; Li M; Shu X
Curr Drug Metab; 2014; 15(7):703-10. PubMed ID: 25255872
[TBL] [Abstract][Full Text] [Related]
44. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
[TBL] [Abstract][Full Text] [Related]
45. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Oostendorp RL; Buckle T; Beijnen JH; van Tellingen O; Schellens JH
Invest New Drugs; 2009 Feb; 27(1):31-40. PubMed ID: 18449471
[TBL] [Abstract][Full Text] [Related]
46. Formation and efflux of ATP-binding cassette transporter substrate 2,4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments.
Vaidya SS; Walsh SW; Gerk PM
Mol Pharm; 2009; 6(6):1689-702. PubMed ID: 19397308
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.
Gao Y; Shen JK; Choy E; Zhang Z; Mankin HJ; Hornicek FJ; Duan Z
Sci Rep; 2016 May; 6():25659. PubMed ID: 27157103
[TBL] [Abstract][Full Text] [Related]
48. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
49. [The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
Wang C; Liu KX
Yao Xue Xue Bao; 2014 May; 49(5):590-5. PubMed ID: 25151726
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
Ou YC; Tang Z; Novotny W; Tawashi M; Li TK; Coleman HA; Sahasranaman S
Br J Clin Pharmacol; 2021 Jul; 87(7):2926-2936. PubMed ID: 33336408
[TBL] [Abstract][Full Text] [Related]
51. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
[TBL] [Abstract][Full Text] [Related]
52. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
[TBL] [Abstract][Full Text] [Related]
53. Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters.
Mohos V; Fliszár-Nyúl E; Ungvári O; Bakos É; Kuffa K; Bencsik T; Zsidó BZ; Hetényi C; Telbisz Á; Özvegy-Laczka C; Poór M
Drug Metab Dispos; 2020 Oct; 48(10):1064-1073. PubMed ID: 32661014
[TBL] [Abstract][Full Text] [Related]
54. Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules.
Vormann MK; Gijzen L; Hutter S; Boot L; Nicolas A; van den Heuvel A; Vriend J; Ng CP; Nieskens TTG; van Duinen V; de Wagenaar B; Masereeuw R; Suter-Dick L; Trietsch SJ; Wilmer M; Joore J; Vulto P; Lanz HL
AAPS J; 2018 Aug; 20(5):90. PubMed ID: 30109442
[TBL] [Abstract][Full Text] [Related]
55. Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
Tapaninen T; Olkkola AM; Tornio A; Neuvonen M; Elonen E; Neuvonen PJ; Niemi M; Backman JT
Clin Transl Sci; 2020 Mar; 13(2):345-351. PubMed ID: 31664782
[TBL] [Abstract][Full Text] [Related]
56. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
57. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
Marchetti S; Pluim D; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Invest New Drugs; 2014 Dec; 32(6):1083-95. PubMed ID: 25078948
[TBL] [Abstract][Full Text] [Related]
58. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
[TBL] [Abstract][Full Text] [Related]
59. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
60. A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.
Strouse JJ; Ivnitski-Steele I; Khawaja HM; Perez D; Ricci J; Yao T; Weiner WS; Schroeder CE; Simpson DS; Maki BE; Li K; Golden JE; Foutz TD; Waller A; Evangelisti AM; Young SM; Chavez SE; Garcia MJ; Ursu O; Bologa CG; Carter MB; Salas VM; Gouveia K; Tegos GP; Oprea TI; Edwards BS; Aubé J; Larson RS; Sklar LA
J Biomol Screen; 2013 Jan; 18(1):26-38. PubMed ID: 22923785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
